for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oragenics Inc

OGEN.A

Latest Trade

0.76USD

Change

-0.04(-5.17%)

Volume

306,178

Today's Range

0.76

 - 

0.79

52 Week Range

0.38

 - 

1.80

As of on the NYSE AMERICAN LLC ∙ Minimum 15 minute delay

Latest Developments

Oragenics Announce Changes In Management And Board Of Directors

May 3 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS ANNOUNCE CHANGES IN MANAGEMENT AND BOARD OF DIRECTORS.ORAGENICS INC - ALAN JOSLYN RESIGNED AS CEO, PRESIDENT AND DIRECTOR.ORAGENICS INC - DURING INTERIM PERIOD BEFORE A NEW CEO IS HIRED, BOARD WILL PROVIDE DIRECTION TO CO.

Oragenics Prices $5.25 Million Common Stock Offering

Nov 20 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS PRICES $5.25 MILLION COMMON STOCK OFFERING.ORAGENICS INC - ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 14.2MLN SHARES OF ITS COMMON STOCK AT PRICE TO PUBLIC OF $0.37 PER SHARE.

Oragenics Says FDA Supports Co’s Pre-IND Development Program For SARS-CoV-2 Vaccine

Oct 6 (Reuters) - Oragenics Inc <OGEN.A>::FDA BROADLY SUPPORTS ORAGENICS’ PRE-IND DEVELOPMENT PROGRAM FOR ITS SARS-COV-2 VACCINE.ORAGENICS - RE-AFFIRMS PLAN TO FILE IND APPLICATION BY END OF 1Q21, BEGIN PHASE 1 STUDY IN EARLY 2Q21 FOR TERRA COV-2.ORAGENICS - FDA HAS REQUESTED ADDITIONAL PRECLINICAL ANIMAL DATA FOR INCLUSION IN IND FILING FOR TERRA COV-2.ORAGENICS - FDA PLANS TO PROVIDE FINAL COMMENTS UPON REVIEWING ADDITIONAL DATA, CO'S PHASE 1 TRIAL PROTOCOL FOR TERRA COV-2.

Oragenics Signs Process Development & Manufacturing Agreement With Avid Bioservices For Coronavirus Vaccine

Aug 20 (Reuters) - Avid Bioservices Inc <CDMO.O>::ORAGENICS SIGNS PROCESS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH AVID BIOSERVICES FOR CORONAVIRUS VACCINE.ORAGENICS INC - AVID WELL POSITIONED TO MEET SIGNIFICANT SCALE-UP REQUIREMENTS FOR NIH-LICENSED SARS-COV-2 SPIKE PROTEIN VACCINE CANDIDATE.ORAGENICS-AVID TO PROVIDE CO WITH ANALYTICAL METHOD DEVELOPMENT, PROCESS DEVELOPMENT AND MANUFACTURING SERVICES TO SUPPORT DEVELOPMENT OF TERRA COV-2.

Oragenics Provides Update On COVID-19 Program

July 10 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS PROVIDES UPDATE ON SARS-COV-2 (COVID-19) PROGRAM.ORAGENICS INC - TERMINATES AG013 ORAL MUCOSITIS DEVELOPMENT PROGRAM.ORAGENICS INC - EXPECT TO USE AVAILABLE CASH TO CONTINUE DEVELOPMENT OF TERRACOV2.ORAGENICS INC - GOAL OF BRINGING COVID-19 VACCINE CANDIDATE INTO HUMAN CLINICAL TRIALS BY EARLY 2021.ORAGENICS INC - ON JULY 9 PRECIGEN, MUTUALLY AGREED TO TERMINATE EXCLUSIVE CHANNEL COLLABORATION AGREEMENT FOR AG013.

Oragenics Files For Shelf Of Up To 18.4 Mln Common Shares By Selling Stockholders

May 29 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS INC FILES FOR SHELF OF UP TO 18.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS – SEC FILING.

Oragenics Acquires Noachis Terra Inc

May 4 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS ACQUIRES NOACHIS TERRA INC., TO DEVELOP ITS TERRACOV2 NIH-GENERATED SARS-COV-2 (COVID 19) VACCINE CANDIDATE UTILIZING “SPIKE PROTEIN”.ORAGENICS INC - AS A RESULT OF DEAL, PAID $1.9 MILLION IN CASH.ORAGENICS - AS A RESULT OF DEAL, ISSUED 9.2 MILLION CO'S SHARES & WARRANTS TO BUY 9.2 MILLION OF CO'S SHARES, CARRYING EXERCISE PRICE OF $1.25/SHARE & 5-YEAR TERM.ORAGENICS INC - PLANS TO FINANCE CLINICAL TRIALS FOR TERRACOV2 WITH ITS AVAILABLE CASH AND ANY GRANT FUNDS THAT MAY BE AWARDED BY BARDA OR NIH.

Oragenics Says May Offer, Issue & Sell Up To $50 Million Of Any Combination Of Common Stock, Warrants & Units

Dec 31 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS SAYS MAY OFFER, ISSUE & SELL UP TO $50 MILLION OF ANY COMBINATION OF COMMON STOCK, WARRANTS & UNITS - SEC FILING.

Oragenics Inc Resumes Phase 2 Clinical Trial Of Ag013 In Oral Mucositis Following Positive Routine Safety Review

Aug 15 (Reuters) - Oragenics Inc <OGEN.A>::ORAGENICS, INC. RESUMES PHASE 2 CLINICAL TRIAL OF AG013 IN ORAL MUCOSITIS FOLLOWING POSITIVE ROUTINE SAFETY REVIEW.ORAGENICS INC - RESUMED ITS PHASE 2 CLINICAL TRIAL OF AG013 FOLLOWING A POSITIVE REVIEW BY AN INDEPENDENT DATA SAFETY MONITORING BOARD.ORAGENICS INC - NOW EXPANDING PHASE 2 TRIAL TO UP TO 45 ADDITIONAL CENTERS IN US AND EU.

EKF Diagnostics Signs Agreement With Oragenics

July 19 (Reuters) - EKF Diagnostics Holdings PLC <EKF.L>::SIGNED AGREEMENT WITH ORAGENICS FOR MANUFACTURING OF ORAGENICS' LANTIBIOTIC BULK DRUG SUBSTANCES IN UNITED STATES.ESTIMATED PARTNERSHIP SHOULD GENERATE MULTI-MILLION DOLLARS IN REVENUES TO EKF DIAGNOSTICS OVER DURATION OF MANUFACTURING AGREEMENT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up